These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 27177843)

  • 21. A Plant-Produced in vivo deglycosylated full-length Pfs48/45 as a Transmission-Blocking Vaccine Candidate against malaria.
    Mamedov T; Cicek K; Miura K; Gulec B; Akinci E; Mammadova G; Hasanova G
    Sci Rep; 2019 Jul; 9(1):9868. PubMed ID: 31285498
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inclusion of an Optimized
    Eacret JS; Parzych EM; Gonzales DM; Burns JM
    J Immunol; 2021 Apr; 206(8):1817-1831. PubMed ID: 33789984
    [No Abstract]   [Full Text] [Related]  

  • 23. Structure of the malaria vaccine candidate Pfs48/45 and its recognition by transmission blocking antibodies.
    Ko KT; Lennartz F; Mekhaiel D; Guloglu B; Marini A; Deuker DJ; Long CA; Jore MM; Miura K; Biswas S; Higgins MK
    Nat Commun; 2022 Sep; 13(1):5603. PubMed ID: 36153317
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Epitope analysis of the malaria surface antigen pfs48/45 identifies a subdomain that elicits transmission blocking antibodies.
    Outchkourov N; Vermunt A; Jansen J; Kaan A; Roeffen W; Teelen K; Lasonder E; Braks A; van de Vegte-Bolmer M; Qiu LY; Sauerwein R; Stunnenberg HG
    J Biol Chem; 2007 Jun; 282(23):17148-56. PubMed ID: 17426022
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Plasmodium falciparum: heterologous synthesis of the transmission-blocking vaccine candidate Pfs48/45 in recombinant vaccinia virus-infected cells.
    Milek RL; DeVries AA; Roeffen WF; Stunnenberg H; Rottier PJ; Konings RN
    Exp Parasitol; 1998 Oct; 90(2):165-74. PubMed ID: 9769246
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Analysis of immune responses against T- and B-cell epitopes from Plasmodium falciparum liver-stage antigen 1 in rodent malaria models and malaria-exposed human subjects in India.
    Joshi SK; Bharadwaj A; Chatterjee S; Chauhan VS
    Infect Immun; 2000 Jan; 68(1):141-50. PubMed ID: 10603380
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Geographical distribution of a variant epitope of Pfs48/45, a Plasmodium falciparum transmission-blocking vaccine candidate.
    Drakeley CJ; Duraisingh MT; Póvoa M; Conway DJ; Targett GA; Baker DA
    Mol Biochem Parasitol; 1996 Oct; 81(2):253-7. PubMed ID: 8898341
    [No Abstract]   [Full Text] [Related]  

  • 28. Immunological Cross-Reactivity between Malaria Vaccine Target Antigen P48/45 in Plasmodium vivax and P. falciparum and Cross-Boosting of Immune Responses.
    Cao Y; Bansal GP; Merino K; Kumar N
    PLoS One; 2016; 11(7):e0158212. PubMed ID: 27438603
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A Pfs48/45-based vaccine to block Plasmodium falciparum transmission: phase 1, open-label, clinical trial.
    Alkema M; Smit MJ; Marin-Mogollon C; Totté K; Teelen K; van Gemert GJ; van de Vegte-Bolmer M; Mordmüller BG; Reimer JM; Lövgren-Bengtsson KL; Sauerwein RW; Bousema T; Plieskatt J; Theisen M; Jore MM; McCall MBB
    BMC Med; 2024 Apr; 22(1):170. PubMed ID: 38649867
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Absence of gamma-interferon-inducible lysosomal thiol reductase in melanomas disrupts T cell recognition of select immunodominant epitopes.
    Haque MA; Li P; Jackson SK; Zarour HM; Hawes JW; Phan UT; Maric M; Cresswell P; Blum JS
    J Exp Med; 2002 May; 195(10):1267-77. PubMed ID: 12021307
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunogenicity and in vitro protective efficacy of a polyepitope Plasmodium falciparum candidate vaccine constructed by epitope shuffling.
    Cai Q; Peng G; Bu L; Lin Y; Zhang L; Lustigmen S; Wang H
    Vaccine; 2007 Jul; 25(28):5155-65. PubMed ID: 17548134
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Poor CD4
    Zaric M; Marini A; Nielsen CM; Gupta G; Mekhaiel D; Pham TP; Elias SC; Taylor IJ; de Graaf H; Payne RO; Li Y; Silk SE; Williams C; Hill AVS; Long CA; Miura K; Biswas S
    Front Immunol; 2021; 12():732667. PubMed ID: 34659219
    [No Abstract]   [Full Text] [Related]  

  • 33.
    Singh SK; Thrane S; Chourasia BK; Teelen K; Graumans W; Stoter R; van Gemert GJ; van de Vegte-Bolmer MG; Nielsen MA; Salanti A; Sander AF; Sauerwein RW; Jore MM; Theisen M
    Front Immunol; 2019; 10():1256. PubMed ID: 31231386
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Cloning and sequencing of the gene coding the sexual stage antigen Pfs48/45 of Plasmodium falciparum].
    Luo S; Yu X; Liu Y; Fang J; Xu J; Li X
    Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi; 1998; 16(6):406-10. PubMed ID: 12078283
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cellular and humoral immune responses to well-defined blood stage antigens (major merozoite surface antigen) of Plasmodium falciparum in adults from an Indian zone where malaria is endemic.
    Kabilan L; Sharma VP; Kaur P; Ghosh SK; Yadav RS; Chauhan VS
    Infect Immun; 1994 Feb; 62(2):685-91. PubMed ID: 8300225
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Characterization of regulatory T-cell responses in humans induced by the P. Falciparum blood stage antigen Pf155/RESA.
    Troye-Blomberg M; Olerup O; Perlmann H; Larsson A; Elghazali G; Fogdell A; Jepsen A; Lepers JP; Pandey JP; Grunewald J
    Behring Inst Mitt; 1994 Dec; (95):97-105. PubMed ID: 7755513
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antibody-Dependent, Gamma Interferon-Independent Sterilizing Immunity Induced by a Subunit Malaria Vaccine.
    Chawla B; Mahajan B; Oakley M; Majam VF; Belmonte A; Sedegah M; Shimp RL; Kaslow DC; Kumar S
    Infect Immun; 2019 Oct; 87(10):. PubMed ID: 31308085
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunological properties of recombinant proteins of the transmission blocking vaccine candidate, Pfs48/45, of the human malaria parasite Plasmodium falciparum produced in Escherichia coli.
    Milek RL; Roeffen WF; Kocken CH; Jansen J; Kaan AM; Eling WM; Sauerwein RW; Konings RN
    Parasite Immunol; 1998 Aug; 20(8):377-85. PubMed ID: 9767603
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunogenicity of an alum-adsorbed synthetic multiple-antigen peptide based on B- and T-cell epitopes of the Plasmodium falciparum CS protein: possible vaccine application.
    de Oliveira GA; Clavijo P; Nussenzweig RS; Nardin EH
    Vaccine; 1994 Aug; 12(11):1012-7. PubMed ID: 7526570
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Predicted disulfide-bonded structures for three uniquely related proteins of Plasmodium falciparum, Pfs230, Pfs48/45 and Pf12.
    Carter R; Coulson A; Bhatti S; Taylor BJ; Elliott JF
    Mol Biochem Parasitol; 1995 May; 71(2):203-10. PubMed ID: 7477102
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.